INTEGRATIVE AND BIOCHEMICAL PARAMETERS IN RATS IN THE SIMULATION OF DOXORUBICIN CHRONIC HEART FAILURE AND DURING THE USE OF Β-ADRENERGIC BLOCKERS

Öz

Objective: In the treatment of chronic heart failure, β-blockers are actively used - Carvedilol, Nebivolol, Metoprolol, Bisoprolol, etc. However, they have a number of serious adverse reactions, and their therapeutic efficacy does not always meet the needs of the clinic. All this prompted the creation of a new potential drug Hypertril (bromide 1-(β-phenylethyl)-4-amino-1,2,4-triazolium. We aimed to conduct a comparative assessment of β-blockers of different generations and "Hypertril" in the conditions of modeling the doxorubicin model of chronic heart failure (CHF) in terms of the effect on biochemical markers of myocardial damage and integrative parameters.

Material and Method: CHF was modeled on 85 white outbred rats weighing 190–220 g by administering doxorubicin at a total dose of 15 mg/kg, nebivolol (10 mg/kg), carvedilol (50 mg/kg), bisoprolol (10 mg/kg), metoprolol (15 mg/kg) and hypertril (3.5 mg/kg) were administered intragastrically once a day as a suspension 1% starchy mucus for 30 days after 14 days of doxorubicin administration. The cardioprotective effect of drugs was assessed by improving integrative parameters (survival, heart mass index, severity in points) and by normalizing cardiospecific markers (NT-proBNP, D-dimer, eNOS, MB-CPK, and ST2).

Result and Discussion: The introduction of Hypertril not only prolonged the life of animals with CHF in comparison with the reference drugs, but also prevented early death and contributed to a decrease in the severity of symptoms (hydrothorax, ascites, scrotal edema). The administration of hypertril to rats with CHF led to a decrease in mortality, a decrease in the heart mass index, in the blood of the main cardiospecific markers to the values of intact animals, and also led to an increase in expression of eNOS, which testified to its significant cardioprotective effect with NO-mimetic effect. The obtained results demonstrated the undoubted advantage of Hypertril over the basic β-adrenergic blockers and experimentally substantiated further in-depth studies to create a drug based on it for the treatment of CHF.

Anahtar Kelimeler

• Bromide 1-(β-phenylethyl)-4-amino-1,2,4-triazolium
• cardioprotection
• chronic heart failure
• hypertril
• endothelial dysfunction
• metoprolol
• β-blockers

DOKSORUBİSİN İLE OLUŞTURULAN KRONİK KALP YETMEZLİĞİ MODELİNDE VE Β-ADRENERJİK BLOKERLERİN KULLANIMI SIRASINDA SIÇANLARDA BÜTÜNLEYİCİ VE BİYOKİMYASAL PARAMETRELER

Öz

Amaç: Kronik kalp yetmezliğinin tedavisinde karvedilol, nebivolol, metoprolol, bisoprolol vb. β-blokerler aktif olarak kullanılmaktadır. Bununla birlikte, bir dizi ciddi yan etkileri bulunmakta olup tedavi edici etkinlikleri her zaman kliniğin ihtiyaçlarını karşılamamaktadır. Bütün bunlar yeni bir potansiyel ilacın (Hypertril, bromür 1-(β-feniletil)-4-amino-1,2,4-triazolyum)) geliştirilmesine yol açmaktadır. Farklı nesil β-blokerlerin ve Hipetrilin farkli koşullar altında (miyokard hasarının biyokimyasal belirteçleri ve integratif parametreler üzerindeki etkisi açısından kronik kalp yetmezliğinin (KKY) doksorubisin modellenmesiyle) karşılaştırmalı bir değerlendirmesinin yapılması amaçlanmıştır.

Gereç ve Yöntem: KKY, doksorubisin toplam 15 mg/kg dozunda uygulanarak 190-220 gram ağırlığındaki 85 beyaz fare üzerinde modellenmiştir. Nebivolol (10 mg/kg), karvedilol (50 mg/kg), bisoprolol (10 mg/kg), metoprolol (15 mg/kg) ve Hipertril (3.5 mg/kg) 14 günlük doksorubisin uygulamasından sonra 30 gün boyunca % 1 nişastalı mukus süspansiyonu olarak günde bir kez intragastrik olarak uygulanmıştır. İlaçların kardiyoprotektif etkisi, integratif parametrelerin iyileştirilmesi (sağkalım, kalp kütle indeksi, noktalardaki şiddet) ve kardiyospesifik belirteçlerin normalleştirilmesiyle (NT-proBNP, D-dimer, eNOS, MB-CPK ve ST2) değerlendirilmiştir.

Sonuç ve Tartışma: Hipertril'in tanıtılması, referans ilaçlara kıyasla KKY'li hayvanların ömrünü uzatmakla kalmamış, aynı zamanda erken ölümü önlemiş ve belirtilerin şiddetinin (hidrotoraks, asit, skrotal ödem) azalmasına katkıda bulunmuştur.
KKY’li farelere hipertril uygulanması, ölüm oranında azalışa, kalp kitle indeksinde düşüşe ve ayrıca NO-mimetik etki ile önemli kardiyoprotektif etkisine tanıklık eden eNOS ifadesinde bir artışa yol açmıştır. Elde edilen sonuçlar, Hypertril'in temel β-adrenerjik blokerlerin üzerindeki tartışmasız avantajını göstermiştir ve KYY tedavisi için buna dayalı bir ilaç oluşturmak amacıyla deneysel olarak derinlemesine çalışmalar yapılmıştır.

Kaynakça

1. 1. Bozkurt, B., Coats, A.J., Tsutsui, H., Abdelhamid, C.M., Adamopoulos, S., Albert, N., Anker, S.D., Atherton, J., Böhm, M., Butler, J., Drazner, M.H., Felker, G.M., Filippatos, G., Fiuzat, M., Fonarow, G.C., Gomez-Mesa J.E., Heidenreich, P., Imamura, T., Jankowska, E.A., Januzzi, J., Khazanie, P., Kinugawa, K., Lam, C.S.P., Matsue, Y., Metra, M., Ohtani, T., Piepoli, M.F., Ponikowski, P., Rosano G.M.C., Sakata, Y., Seferovic, P., Starling, R.C., Teerlink, J.R., Vardeny, O., Yamamoto, K., Yancy, C., Zhang, J., Zieroth, S. (2021). Universal definition and classification of heart failure: A report of the Heart Failure Society of America, Heart Failure Association of the European Society of Cardiology, Japanese Heart Failure Society and Writing Committee of the Universal Definition of Heart Failure: Endorsed by the Canadian Heart Failure Society, Heart Failure Association of India, Cardiac Society of Australia and New Zealand, and Chinese Heart Failure Association. European Journal of Heart Failure, 23(3), 352-380. [CrossRef]
2. 2. Urbich, M., Globe, G., Pantiri, K., Heisen, M., Bennison, C., Wirtz, H.S., Di Tanna, G.L. (2020). A systematic review of medical costs associated with heart failure in the USA (2014-2020). PharmacoEconomics, 38, 1219-1236. [CrossRef]
3. 3. Watanabe, K., Ohta, Y., Inoue, M., Ma, M., Wahed, M.I., Nakazawa, M., Hasegawa, G., Naito, M., Fuse, K., Ito, M., Kato, K., Hanawa, H., Kodama, M., Aizawa, Y. (2001). Bisoprolol improves survival in rats with heart failure. Journal of Cardiovascular Pharmacology, 38(1), S55-S58. [CrossRef]
4. 4. Konyakhin, A.Yu. (2009). Modern pathogenetic approaches to the correction of myocardial ischemia. Abstract of the dissertation of the doctor of medical sciences, 47.
5. 5. Wenningmann. N., Knapp, M., Ande, A., Vaidya, T.R., Ait-Oudhia, S. (2019). Insights into doxorubicin-induced cardiotoxicity: Molecular mechanisms, preventive strategies, and early monitoring. Molecular Pharmacology, 96(2), 219-232. [CrossRef]
6. 6. Bien, S., Riad, A., Ritter, C.A., Gratz, M., Olshausen, F., Westermann, D., Kroemer, H.K. (2007). The endothelin receptor blocker bosentan inhibits doxorubicin-induced cardiomyopathy. Cancer Research, 67(21), 10428-10435. [CrossRef]
7. 7. Mazur, I., Belenichev, I., Kucherenko, L., Bukhtiyarova, N., Puzyrenko, A., Khromylova, O., Gorchakova, N. (2019). Antihypertensive and cardioprotective effects of new compound 1-(β-phenylethyl)-4-amino-1, 2, 4-triazolium bromide (Hypertril). European Journal of Pharmacology, 853, 336-344. [CrossRef]
8. 8. Mazur, I.A., Belenichev, I.F., Kolesnik, Yu.M., Kucherenko, L. (2010). 1-(β-phenylethyl)-4-amino-1,2,4-thiatriazolium (MT) bromide with cardioprotective, anti-ishemic, antihypertensive, antioxidant, protein syntetic and energy-tropic action. Patent 2404974.

9. 9. Chekman, I.S., Belenichev, I.F., Kucherenko, L.I., Mazur, I.A., Nagornaia, E.A., Bukhtiiarova, N.V. (2013). Parniuk NV. NO-dependent mechanisms of cardioprotective activity of mt preparation during course administration to SHR rats. Eksperimental’naia i Klinicheskaia Farmakologiia, 76(8), 24-26.
10. 10. Khloponin, D.P. (2009). Analysis of possible mechanisms of pharmacological reversal of cardiac remodeling in chronic heart failure (Doctoral dissertation). Volgograd State Medical University, Volgograd.
11. 11. Sidorov, A.V. (2013). Neurohumoral aspects in the implementation of prognostic effects of β-andreblockers and ACE in chronic heart failure. Doctoral dissertation. Staraya Kupavna; 412 p.
12. 12. Cosentino, F., Bonetti, S., Rudolf, R., Eto, M., Werner-Felmayer, G., Volpe, M., Lüscher, T.F. (2002). Nitric-oxide-mediated relaxations in salt-induced hypertension: Effect of chronic β1-selective receptor blockade. Journal of Hypertension, 20(3), 421-428. [CrossRef]
13. 13. Chen, Y., Hong, X. (2016). Effects of carvedilol reduce conjunctivitis through changes in inflammation, NGF and VEGF levels in a rat model. Experimental and Therapeutic Medicine, 11(5), 1987-1992. [CrossRef]
14. 14. Kolesnik, Yu.M., Chekman, І.S., Mazur, I.A., Belenichev, I.F., Gorchakova, N.O., Nagorna, O.O. (2014). Mechanisms for the development of endothelial dysfunction and prostate endothelial protectors. Journal of the National Academy of Medical Sciences of Ukraine, 20(3), 289-299.
15. 15. Maisel, A.S., Somma, S.D. (2016). Do we need another heart failure biomarker: Focus on soluble suppression on tumoregenicity 2 (sST2). European Heart Journal, 38 (30), 2325-2333. [CrossRef]
16. 16. Hayakawa, H., Komada, Y., Hirayama, M., Hori, H., Ito, M., Sakurai, M. (2001). Plasma levels of natriuretic peptides in relation to doxorubicin-induced cardiotoxicity and cardiac function in children with cancer. Medical and Pediatric Oncology, 37 (1), 4-9. [CrossRef]
17. 17. Octavia, Y., Tocchetti, C.G., Gabrielson, K.L., Janssens, S., Crijns, H.J., Moens A.L. (2012). Doxorubicin-induced cardiomyopathy: From molecular mechanisms to therapeutic strategies. Journal of Molecular and Cellular Cardiology, 52(6), 1213-1225. [CrossRef]
18. 18. Neilan, T.G., Blake, S.L., Ichinose, F., Raher, M.J., Buys, E.S., Jassal, D.S., Furutani, E., Perez-Sanz, T.M., Graveline, A., Janssens, S.P., Picard, M.H., Scherrer-Crosbie, M., Bloch, K.D. (2007). Disruption of nitric oxide synthase 3 protects against the cardiac injury, dysfunction, and mortality induced by doxorubicin. Circulation, 116, 506-514. [CrossRef]
19. 19. Belenichev, I., Gorbachova, S., Pavlov, S., Bukhtiyarova, N., Puzyrenko, A., Brek, O. (2021). Neurochemical status of nitric oxide in the settings of the norm, ishemic event of central nervous system, and pharmacological intervention. Georgian Medical New, 315, 169-176.
20. 20. Trujillo. M., Naviliat, M., Alvarez, M.N., Peluffo, G., Radi, R. (2000). Peroxynitrite biochemistry: formation, reactions and detection. Analusis, 28(6), 518-527. [CrossRef]
21. 21. Gilleron, M., Marechal, X., Montaigne, D., Franczak, J., Neviere, R., Lancel, S. (2009). NADPH oxidases participate to doxorubicin-induced cardiac myocyte apoptosis. Biochemical and Biophysical Research Communications, 388(4), 727-731. [CrossRef]
22. 22. Nicol, M., Sadoune, M., Polidano, E., Launay, J.M., Samuel, J.L., Azibani, F. (2021). Doxorubicin-induced and trastuzumab-induced cardiotoxicity in mice is not prevented by metoprolol ESC Heart Failure, Published online in Wiley Online Library, 8(2), 928-937. [CrossRef]
23. 23. Liu, B., Li, H., Qu, H., Sun, B. (2006). Nitric oxide synthase expressions in ADR-induced cardiomyopathy in rats. BMB Reports, 39(6), 759-765. [CrossRef]
24. 24. Belenichev, I.F., Bak, P.G., Abramov, A.V., Kucherenko, L.I., Bukhtiyarova, N.V., Rizhenko, V.P. (2021). ECG analysis in the simulation of chronic heart failure in rats and course administration of a new potential drug “Hypertril”. Pharmacology and Toxicology, 15(1), 20-30.
25. 25. Tassigny, A., Berdeaux, A., Souktani, R., Henry, P., Ghaleh, B. (2008). The volume-sensitive chloride channel inhibitors prevent both contractile dysfunction and apoptosis induced by doxorubicin through PI3kinase, Akt and Erk 1/2. European Journal of Heart Failure, 10(1), 39-46. [CrossRef]
26. 26. Ryzhov, O.A., Ryzhenko, V.P., Levich, S.V., Belenichev, I.F. (2017). Analysis of influence of quantum chemical descriptors on NO-scavenger properties among xanthine derivatives, Biological Markers and Guided Therapy, 4(1), 39-48. [CrossRef]
27. 27. Youn, H.J., Kim, H.S., Jeon, M.H., Lee, J.H., Seo, Y.J., Lee, Y.J., Lee, J.H. (2005). Induction of caspase-independent apoptosis in H9c2 cardiomyocytes by adriamycin treatment. Molecular and Cellular Biochemistry, 270(1), 13-19. [CrossRef]
28. 28. Bak, P.G., Belenichev, I.F., Kucherenko, L.I., Abramov, A.V., Khromylоva, O.V. (2021). Morpho-functional indicators changes of rats’ myocardium in experimental doxorubicin-induced chronic heart failure and its pharmacological modulation with new 4-amino-1,2,4-triazole derivative. Pharmacia, 68(4), 919-925. [CrossRef]